FGFR3 and urinary bladder cancer: The approval by the FDA of erdafitinib—a small molecule targeting FGFR3—in 2019 for the treatment of bladder cancer [5] is an important addition to the relatively small arsenal against this cancer and signifies the intent to support more targeted therapies as well as chemotherapy and immunotherapy, which is in line with our aim in this work.